Cerebral paralysis therapy;Tratamiento de la paralisis cerebral

Revista de Neurologia

Volumn 25, Issue 141, 1997, Pages 728-739

  Papazian, O ^a   Alfonso, I ^a  

^a MIAMI CHILDREN'S HOSPITAL   (United States)

Author keywords

baclofen; botulinum toxin; cerebral palsy

Indexed keywords

AMINO ACID RECEPTOR BLOCKING AGENT; BACLOFEN; BOTULINUM TOXIN; DANTROLENE; DIAZEPAM; LEVODOPA; TRIHEXYPHENIDYL; ANTIPARKINSON AGENT; BOTULINUM TOXIN A; CENTRAL MUSCLE RELAXANT;

CEREBRAL PALSY; CONFERENCE PAPER; HUMAN; INTRATHECAL DRUG ADMINISTRATION; NEWBORN; ORAL DRUG ADMINISTRATION; INTRASPINAL DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; PHYSIOTHERAPY; REVIEW; RHIZOTOMY; SPEECH THERAPY;

ANTI-DYSKINESIA AGENTS; BACLOFEN; BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; COMBINED MODALITY THERAPY; HUMANS; INJECTIONS, SPINAL; LANGUAGE THERAPY; MUSCLE RELAXANTS, CENTRAL; PHYSICAL THERAPY MODALITIES; RHIZOTOMY;

EID: 0031132842     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (69)

1. Kuban KCK, Leviton A. Cerebral palsy. N Engl J Med 1994; 330: 188-195.
2. Stanley FJ, Watson L. Trends in perinatal mortality and cerebral palsy in Western Australia, 1967 to 1985. BMJ 1992; 304: 1658-1663.
3. Evans PM, Evans SJW, Alberman E. Cerebral palsy: why we must plan for survival. Arch Dis Child 1990; 65: 1329-1333.
4. Rumeau-Rouquette C, du Mazabrun C, Milika A, Dequae L. Motor disability in children in three birth cohorts. Int J Epidemiol 1992; 21: 359-366.
5. Newacheck PW, Taylor WR. Childhood chronic illness: prevalence, severity, and impact. Am J Public Health 1992; 82: 364-371.
6. Bryce RL, Halperin ME, Sinclair JC. Association between indicators of perinatal asphyxia and adverse outcome in the term infant: a methodological review. Neuroepidemiolology 1985; 4: 24-38.
7. Johnston MV, Trescher WH. Excitatory aminoacids in development and pathophysiology. In Lou HC, Greisen G, Larsen JF, eds. Brain lesions in the newborn. Copenhagen: Munksgaard, 1994; 76-87.
8. Legido A. Pathophysiology of perinatal hypoxic-ischemic encephalopathy. Acta Neuropediatr 1994; 1: 97-109.
9. Volpe JJ. Perinatal hypoxic ischemic brain injury: overview. In Fukuyama Y, Suzuki Y, Kamoshita S, Casaer P, eds. Fetal and perinatal neurology. Basel: Karger, 1992; 232-252.
10. Leviton A, Paneth N. White matter damage in preterm newborns: an epidemiologic perspective. Early Hum Dev 1990; 24: 1-22.
11. Pidcock FS, Graziani LJ, Stanley C, et al. Neurosonographic features of periventricular echodensities associated with cerebral palsy in preterm infants. J Pediatr 1990; 116: 417-22.
12. Mutch L, Alberman E, Hagberg B, et al. Cerebral palsy epidemiology: where are we now and where are we going? Dev Med Child Neurol 1992; 34: 547-51.
13. Nelson KB, Ellemberg JH. Epidemiology of cerebral palsy. Adv Neurol 1978; 19: 421.
14. Filloux FM. Neuropathophysiology of Movement Disorders in Cerebral Palsy. J Child Neurol 1996; 11 (Suppl 1): S5-S12.
15. Campbell SK. Quantifying the effects of Interventions for movement disorders resulting from cerebral palsy. J Child Neurol 1996; 11 (Suppl 1): S61-S70.
16. Nelson KB, Ellenberg JH. Children who 'outgrew' cerebral palsy. Pediatrics 1982; 69: 529-536.
17. Kyllerman M, Bager B, Bensch J, Billie B, Olow I, Voss H. Dyskinetic cerebral palsy. I. Clinical categories, associated neurological abnormalities and incidence. Acta Paediatr Scand 1982; 71: 543-550.
18. Davis RM, Cullen RF, Flitter MA, et al. Control of spasticity and involuntary movements. Cerebellar stimulation. Appl Neurophysiol 1977; 40: 135-40.
19. Waltz JM. Spinal cord stimulation for palsies? Patient Care 1979; 13: 188.
20. Albright AL. Intrathecal baclofen in cerebral palsy movement disorders. J Child Neurol 1996: 11 (Suppl 1): S29-S35.
21. Pranzatelli MA. Oral pharmacotherapy for the movement disorders of cerebral palsy. J Child Neurol 1996; 11 (Suppl 1): S13-S22.
22. Barry MJ. Physical therapy interventions for patients with movements disorders due to cerebral palsy. J Child Neurol 1996; 11 (Suppl 1): S51-S60.
23. Koman LA, Mooney JF, Smith BP. Neuromuscular Blockade in the management of cerebral palsy. J Child Neurol 1996; 11 (Suppl 1): S23-S28.
24. Abbott R. Sensory rhizotomy for the treatment of childhood spasticity. J Child Neurol 1996; 11 (Suppl 1): S36-S42.
25. De Salles AAF. Role of stereotaxis in the treatment of cerebral palsy. J Child Neurol 1996; 11 (Suppl 1): S43-S50.
26. Bobath K, Bobath B. The neuro-developmental treatment. In Scrutton D, ed. Management of Motor Disorders of Children with Cerebral Palsy. Philadelphia: JB Linpincott, 1984; 6-18.
27. Semans S. A neurophysiological approach to treatment of cerebral palsy: introduction to the Bobath method. In Roshtein JM, ed. Cerebral Palsy: discussion and Review. Vol I. Alexandria, VA: American Physical Therapy Association, 1995; 191-197.
28. Bly L. A historical and current view of the basis of NTD. Pediatr Phys Ther 1991; 3: 131-35.
29. Girolani GL, Campbell SK. Efficacy of a neuro-developmental treatment program to improve motor control in infants born prematurely. Pediatr Phys Ther 1994; 6: 175-184.
30. Kluzik J, Fetters L, Coryell J. Quantification of control: a preliminary study of neurodevelopmental treatment on reaching in children with spastic cerebral palsy. Phys Ther 1990; 70: 65-78.
31. Rothberg AD, Goodman M, Jacklyn LA, Cooper PA. Six year follow-up of early physiotherapy intervention in very low birth weight infants. Pediatrics 1991; 88: 547-52.
32. Votja V. The basic elements of treatment according to Votja. In Scrutton D, ed. Management of Motor Disorders of Children with Cerebral Palsy. Philadelphia: PA: JB Lippincott, 1984; 75-85.
33. Kanda T, Yuge M, Yamori Y, et al. Early physical therapy in the treatment of spastic diplegia. Dev Med Child Neurol 1984; 26: 438-444.
34. Damiano DL, Kelly LE, Vaughn CL. Effects of quadriceps femoris muscle strengthening on crouch gait in children with spastic diplegia. Phys Ther 1995; 75: 658-71.
35. Olney SJ. New developments in the biomechanics of gait in children with cerebral palsy. In Campbell SK, ed. Topics in Pediatrics, Lesson 1. Alexandria, VA: American Physical Therapy Association, 1990; 1-10.
36. Cusick B. Splints and casts: managing foot deformities in children with spastic diplegia. Phys Ther 1988; 68: 1903-1912.
37. Bertoti DB. Effect of short leg casting on ambulation in children with cerebral palsy. Phys Ther 1986; 66: 1522-1529.
38. Harris SR, Riffle K. Effects of inhibitive ankle-foot orthoses on standing balance in a child with cerebral palsy. Phys Ther 1986; 66: 663-667.
39. Myhr U, von Wendt L, Norrlin S, Radell U. Five- year follow-up of functional sitting position in children with cerebral palsy. Dev Med Child Neurol 1995; 37: 587-96.
40. Cosgrove IP, Corry IS, Grahm HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994; 36: 386-96.
41. Calderón-González R, Calderón-Sepúlveda RF, Rincon-Reyes M, et al. Botulinum toxin A in management of cerebral palsy. Pediatr Neurol 1994; 10: 284-88.
42. Calderon-González R, Calderón-Sepúlveda RF. Pathophysiology of spasticity and the role of botulinum toxin in his treatment. Acta Neuropediatrica 1994; 1: 44-57.
43. Chutorian AM, Root L. Management of spasticity in children with botulinum-A toxin. Int Pediatr 1994; 9 (Suppl 1): 11-16.
44. Koman LA, Ferrari E, Mubarak S et at. Botulinum toxin type A (BTA) in the treatment of lower-limb spasticity associated with cerebral palsy. Dev Med Child Neurol 1995; 37: 19-20.
45. Corry IS, Cosgrove IP, Duffy CM et al. Botulinum toxin A as an alternative to serial casting in the conservative management of equinus in cerebral palsy. Dev Med Child Neurol 1995; 37: 20-21.
46. Denislic M, Meh D. Botulinum toxin the treatment of cerebral palsy. Neuropediatrics 1995; 26: 249-52.
47. Schantz EJ, Johnson EA. Dose standardization of botulinum toxin. Lancet 1990; 335: 421.
48. Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 1988; 3: 333-35.
49. Jankovic J. Botulinum toxin in movement disorders. Curr Opin Neurol 1994; 7: 358-66.
50. Scott AB. Botulinum toxin injection of eye muscle to correct strabism. Trans Am Ophthalmol Soc 1981; 79: 734-770.
51. Duchen LW. Changes in the electron microscopic structure of slow and fast skeletal muscle fibers of the mouse after the local injection of botulinum toxin. J Neurol Sci 1971; 14: 61-74.
52. Shaari CM, Sanders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerv 1993; 16: 964-969.
53. Sutherland DH, Kaufman KR, Wyatt MP, Chambers HG. Injection of botulinum A toxin into the gastrocnemius muscle of patients with cerebral palsy: A 3-D motion analysis study. Dev Med Child Neurol 1995; 37: 17-18.
54. Abbott R, Johann-Murphy M, Shimminski-Maher T, et al. Selective dorsal rhizotomy: outcome and complications in treating spastic cerebral palsy. Neurosurgery 1993; 33: 851-857.
55. Adams J, Cahan L, Perry J, Beeler L. Foot contact pattern after following selective dorsal rhizotomy. Pediatr Neurosurg 1995; 23: 76-81.
56. Berman B, Vaugahn C, Peacock W. The effect of rhizotomy on movement in patients with cerebral palsy. Am J Occcup Ther 1990; 44: 511-16.
57. Bloom KK, Nazar GB. Functional assessment following selective posterior rhizotomy in spastic cerebral palsy. Childs Nerv Syst 1994; 10: 84-86.
58. Boscarino L, Ounpuu S, Davis R, et al. Effects of selective dorsal rhizotomy on gait in children with cerebral palsy. J Pediatr Orthop 1993; 13: 174-179.
59. Cahan LD, Adams JM, Perry J, Beeler LM. Instrumented gait analysis after selective dorsal rhizotomy. Dev Med Child Neurol 1990; 32: 1037-1043.
60. Prats AR, Morrison G, Jayakar P, et al. Selective dorsal rhizotomy for children with spasticity. Int Pediatr 1991; 6: 327-30.
61. Peacock WJ, Staude LA. Management of spasticity in Cerebral Palsy. 1992; 7: 173-180.
62. Abbott R. Sensory rhizotomy for the treatment of childhood spasticity. J Child Neurol 1996; 11 (Suppl 1): S36-S42.
63. Albright AL, Cervi A, Singletary J. Intrathecal baclofen for spasticity in cerebral palsy. JAMA 1991; 265: : 1418-22.
64. Albright AL, Barron WB, Fasick MP, et al. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 1993; 270: 2475-2477.
65. Albright AL, Barry MJ, Fasick MP, Janosky J. Effects of continuous intrathecal baclofen infusion and selective posterior rhizotomy on upper extremity spasticity. Pediatr Neurosurg 1995; 23: 82-85.
66. Albright AL, Barry MJ, Fasick MP, et al. Continuous intrathecal baclofen infusion for symptomatic generalized dystonia. Neurosurgery 1996; 38: 934-939.
67. Albright AL. Intrathecal baclofen in cerebral palsy movement disorders. J Child Neurol 1996; 11 (Suppl 1): S29-S35.
68. Muller H. Treatment of severe spasticity: results of a multicentric trial conducted in Germany involving the intrathecal infusion of baclofen by an implantable drug delivery system. Dev Med Child Neurol 1992; 34: 739-45.
69. Campbell SK, Almeida GL, Penn RD, Corcos DM. The effects of intrathecally administered baclofen on function in patients with spasticity. Phys Ther 1995; 75: 352-62.